Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BNBX vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMRA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–2 Matrix Metrics)

BMRA Overall Winner 6-Pillar Tally: BNBX 2 – 2 BMRA (2 Tie) Matrix Metrics: BNBX 2 – 5 BMRA

As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over BNB Plus Corp. (BNBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BNBX carries a Unified Composite Score of 37.7/100 (SELL) at $0.16 (N/M Forward P/E, -636.4% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin).

  • Growth vs. Quality Trade-Off: BMRA earns the overall head-to-head edge with a stronger Unified Composite Score (44.5/100 HOLD vs. BNBX 37.7/100 SELL) and 0.67β · 62% Vol risk profile, whereas BNBX leads top-line expansion (+34.3% YoY revenue growth, 1.27x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BNBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BNBX vs BMRA
BNBX US Equity
BNB Plus Corp.
Finance Services
$0.16
-56.75% 1D
Market Cap $2.7M
TTM Revenue $2.1M
Forward P/E N/M
Beta / 30D Vol 1.68β · 227% Vol
Unified Composite Score
37.7 / 100 SELL
Tech 40.0 Fund 46.0 Flow 50.0 Mom 48.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.6%), weak momentum, RSI 22
RSI-14: 21.9 · SMA20: $0.39 · SMA50: $0.44
BMRA NASDAQ Head-to-Head Winner
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (BNBX 2 – 2 BMRA)

Columns: Metric · BNBX · BMRA
1. Valuation Multiples BNBX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 1.27x N/M
EV / Revenue 0.8x 1.1x
2. Growth & Scale BNBX
Revenue Growth (YoY) +34.3% -8.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.1M $4.3M
Market Cap $2.7M $6.0M
3. Profitability & Quality BMRA
Gross Margin 46.8% 0.9%
Operating Margin -636.4% -125.2%
Net Profit Margin 0.0% -115.5%
Return on Equity (ROE) -306.8% -113.8%
4. Balance Sheet & Cash Flow BMRA
Cash Generation (TTM) -$32M EBITDA -$3.2M
Cash Flow Margin N/A -73.5%
Net Cash / Leverage -$949,091 Net Debt (0.00x D/E) $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Asset Management Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BNBX (2) vs BMRA (5)
Institutional Metric BNBX BMRA Criterion Row Edge
Market Capitalization
Scale
$2.7M $6.0M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+34.3% -8.3% Higher Growth BNBX
Operating Margin (TTM)
Profitability
-636.4% -125.2% Higher Margin BMRA
Net Profit Margin
Profitability
0.0% -115.5% Higher Margin BNBX
Return on Equity (ROE)
Capital Efficiency
-306.8% -113.8% Higher ROE BMRA
52-Week Range Position
Momentum
0% ($0–$7) 5% ($1–$3) Stronger Trend BMRA
Beta / 30D Volatility
Risk Regime
1.68β · 227% Vol 0.67β · 62% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
37.7 / 100 (SELL) 44.5 / 100 (HOLD) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$2.1M $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.8% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.27x PEG · 0.8x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M EBITDA (-$949,091 Net Debt (0.00x D/E)) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BMRA +51.06 pp
BNBX: -67.4% · BMRA: -16.34%
3M Horizon BMRA +51.24 pp
BNBX: -71.9% · BMRA: -20.66%
6M Horizon BMRA +48.62 pp
BNBX: -89.94% · BMRA: -41.32%
1Y Horizon BMRA +62.36 pp
BNBX: -94.76% · BMRA: -32.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BNBX Revenue BMRA Revenue BNBX Op. Margin BMRA Op. Margin Margin Leader
FY2019 $10M $10M -169.3% -46.4% BMRA
FY2020 $0M $10M -649.0% -41.0% BMRA
FY2021 $10M $10M -147.9% -104.2% BMRA
FY2022 $20M $20M -76.9% -24.0% BMRA
FY2023 $10M $10M -81.9% -135.3% BNBX
FY2024 $0M $10M -646.7% -117.6% BMRA
FY2025 $0M $10M -750.9% -96.7% BMRA
FY2026 N/A $0M N/A -119.5% BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BNBX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BNBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BNBX Moat Profile Cyclical / Execution-Driven Positioning
Asset Management Operator
Competes within the Asset Management value chain with $2.7M market capitalization and -636.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BNBX vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over BNB Plus Corp. (BNBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BNBX carries a Unified Composite Score of 37.7/100 (SELL) at $0.16 (N/M Forward P/E, -636.4% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin). Growth vs. Quality Trade-Off: BMRA earns the overall head-to-head edge with a stronger Unified Composite Score (44.5/100 HOLD vs. BNBX 37.7/100 SELL) and 0.67β · 62% Vol risk profile, whereas BNBX leads top-line expansion (+34.3% YoY revenue growth, 1.27x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BNBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BNBX leads the Growth & Scale pillar: BNBX posts +34.3% YoY revenue growth and +0.0% YoY earnings growth on $2.1M TTM revenue (46.8% gross margin, -636.4% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BNBX cumulative revenue shifted +0.0% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, BNBX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

BNBX screens cheaper on headline valuation multiples. BNBX trades at N/M Forward P/E, N/M Trailing P/E, 1.27x PEG, and 0.8x EV/Revenue (unreported EBITDA margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BNBX (-306.8% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, BNBX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.68β · 227% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.